LIM KINASE 1 (LIMK1) AND METASTASIS, THE SEARCH FOR LIMK1 INHIBITORS

LIM 激酶 1 (LIMK1) 和转移，寻找 LIMK1 抑制剂

• 批准号: nhmrc : 356216
• 负责人: A/Pr Ian Street
• 金额: $ 30.76万
• 依托单位: St. Vincent's Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/lim-kinase-1-limk1-inhibitors/81428
• 关键词: LIM; KINASE; LIMK1; METASTASIS; SEARCH

Disseminated cancer, unlike the localized disease, can rarely be cured by drug therapy. We have found that LIM kinase (LIMK1), a protein that was discovered in our laboratory, plays an important role in controlling the ability of tumour cells to spread, a process called metastasis. Thus, this protein becomes an important target for the development of new drug therapies to prevent the spread of cancer. Importantly, we have demonstrated that (1) inhibiting LIMK1 blocks the formation of metastatic tumours in mice, and (2) introduction of this protein into tumour cells makes them more invasive. In addition, we find that the level of LIMK1 is much higher in human tumour cell lines that have the propensity to easily form tumours in mice. Also, measuring the level of this protein in cancer cells that spread to other organs shows that it is at significantly elevated levels when compared to normal tissue. The goals of this research are to: (1) understand whether the ability of LIMK1 to regulate tumour spreading and invasiveness correlates with its ability to control metastasis; (2) examine in human tumour samples whether the levels of LIMK1 correlate with the development of metastatic tumours; and (3) search for drugs that can inhibit the activity of this protein. The results from this research will be highly significant because LIMK1 levels are likely to be an important marker for which tumours will become metastatic. It is possible that, at the time of tumour diagnosis, LIMK1 measurements will enable the clinician to predict whether an individual tumour will become metastatic. Secondly, this protein is a novel drug development target. Drugs that inhibit this protein may block the ability of tumours to invade and metastasise.

与局限性疾病不同，播散性癌症很少能通过药物治疗治愈。我们发现LIM激酶（LIMK 1）是我们实验室发现的一种蛋白质，在控制肿瘤细胞扩散的能力中起着重要作用，这一过程称为转移。因此，这种蛋白质成为开发新药物疗法以防止癌症扩散的重要靶点。重要的是，我们已经证明，（1）抑制LIMK 1可以阻断小鼠转移性肿瘤的形成，（2）将这种蛋白质引入肿瘤细胞使它们更具侵袭性。此外，我们发现LIMK 1的水平在人类肿瘤细胞系中要高得多，这些细胞系具有在小鼠中容易形成肿瘤的倾向。此外，测量扩散到其他器官的癌细胞中这种蛋白质的水平表明，与正常组织相比，它处于显着升高的水平。这项研究的目的是：（1）了解LIMK 1调节肿瘤扩散和侵袭的能力是否与其控制转移的能力相关;（2）在人类肿瘤样本中检查LIMK 1的水平是否与转移性肿瘤的发展相关;（3）寻找可以抑制这种蛋白质活性的药物。这项研究的结果将非常重要，因为LIMK 1水平可能是肿瘤转移的重要标志。在肿瘤诊断时，LIMK 1测量将使临床医生能够预测个体肿瘤是否会转移。其次，这种蛋白质是一种新的药物开发靶点。抑制这种蛋白质的药物可能会阻止肿瘤侵袭和转移的能力。